You are here:Home-Research Areas-Cancer-Blood Cancer

Request The Product List ofBlood Cancer Blood Cancer

Cat. No. Product Name CAS No. Information

BAY 2402234


BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM (human full-length DHODH); binds the ubiquinone binding site of DHODH between the N-terminal helices; causes dose-dependent upregulation of CD11b with EC50s of 3.16 nM in MOLM-13 cells and 0.96 nM in HEL cells, inhibits the proliferation of THP-1 cells with an IC50 of 2.6 nM, as well as nine other leukemia cell lines representing diverse AML subtypes (IC50=0.08-8.2 nM); BAY 2402234 shows monotherapy efficacy and differentiation induction across multiple AML subtypes both in vitro and in vivo.

Blood Cancer

Phase 1 Clinical




Glasdegib (PF-04449913) is a potent, orally bioavailable smoothened (SMO) inhibitor with IC50 of 5 nM in the Gli-luciferase reporter assays, binds to human SMO (AA181-787) with IC50 of 4 nM; inhibits sonic hedgehog (Shh) stimulated luciferase expression in mouse embryonic fibroblasts with an IC50 of 6.8 nM, significantly reduces medulloblastoma growth in a Ptch1+/-p53+/- allograft model at doses that decreased murine Shh target gene expression; reduced downstream GLI2 protein and cell cycle regulatory gene expression in humanized stromal co-cultures and LSC (leukemia stem cells) xenografts.

Blood Cancer

Phase 3 Clinical




AP1903 (Rimiducid, AP-1903) is a potent, specific synthetic ligand of FKBP Phe36Val mutant (F36V-FKBP) with binding IC50 of 1.8 nM; displaces the Fluoresceinated FK506 probe from F36V-FKBP with an IC50 of 5 nM, but shows negligible binding activity to the wild-type protein; elicited potent and dose-dependent apoptotic death of human fibrosarcoma line HT1080 expressing dimerizer-dependent Fas constructs with EC50 of 0.1 nM; induces activation of Fas signaling both in vitro and in vivo, AP1903 is a lipid-permeant dimerizing ligand induced oligomerization and activation of FKBP.

Blood Cancer

Phase 3 Clinical




MIK665 (S-64315, MIK-665) is a novel potent, selective Mcl-1 inhibitor with potential pro-apoptotic and antineoplastic activities; binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.

Blood Cancer

Phase 1 Clinical




ARQ-531 (ARQ531) is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, respectively; also ptently inhibits 45 kinases with >50% inhibition at 200 nM (TEC, BMX, LCK, TRK family kinases etc.); does not require the C481S residue to bind to BTK, inhibits CD69 expression on CD20+ B-cells with IC50 of 42 nM (Ibrutinib, IC50=3 nM); ARQ-531 inhibits proliferation of malignant cells both sensitive and resistant to ibrutinib (SUDHL6 Cell GI50=80 nM), ARQ 531 is superior to Ibrutinib in a TCL1 highly predictive adoptive transfer model of CLL.

Blood Cancer

Phase 1 Clinical




IACS-010759 (IACS010759) is a small molecule inhibitor of mitochondrial oxidative phosphorylation (OXPHOS), targets complex I of the mitochondrial electron transport chain; decreases cell viability and increases apoptosis with EC50 values between 1 nM-50 nM across multiple lines; robustly inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS, reduces aspartate production that leads to impaired nucleotide biosynthesis; potently inhibits tumor growth of brain cancer and AML in vivo.

Blood Cancer

Phase 1 Clinical




S55746 (BCL201, Servier-1) is a novel potent, selective, orally bioavailable inhibitor of BCL-2 with Ki of 1.3 nM, 70- 400 fold selectivity over BCL-XL, on significant binding to MCL-1 and BFL-1; potently induces RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM, exhibits a much weaker activity in H146 (IC50 1.7 μM), a BCL-XL-dependent cell line; concentration-dependently disrupts the BCL-2/BAX complex in RS4;11 cells, selectively induces apoptosis through BCL-2 inhibition in a BAX/BAK-dependent manner; induces cell death in a panel of non-Hodgkin lymphoma cells; inhibits xenograft growth in RS4;11 and Toledo models.

Blood Cancer

Phase 1 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us